EDIGENE INC.

In News

EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies - Business Wire

Business Wire - Nov 07, 2022

Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Sep 15, 2021

Abcam acquires EdiGene’s cell lines and lysates portfolio - pharmatimes.com

pharmatimes.com - Jul 16, 2019

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy - medicalxpress.com

medicalxpress.com - Sep 08, 2025

Some of the Key Players in Next Generation Genome Editing Market: - Insightace Analytic

Insightace Analytic - Oct 22, 2024

EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0-based in vivo RNA Editing Therapies in NHP Model at the 26th Annual Meeting of ASGCT via Oral Presentation - Business Wire

Business Wire - May 02, 2023

EdiGene finishes successful round of financing - China Daily Global Edition

China Daily Global Edition - Apr 21, 2021

Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Jul 26, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment